Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site. The ad also hit a nerve with the pharma industry, lawmakers and some industry groups. The ad ...

Telehealth stock Hims & Hers (HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy. The ad criticized the ...

Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday as the company’s controversial Super Bowl ad on Sunday continued to ...

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth company. A big part of that is related to its Super Bowl LIX ad ...

Earlier in February, Hims & Hers Health rallied as it was set to debut its controversial Super Bowl ad, where it positioned itself as the “affordable, doctor-trusted, formulated in the US ...

The ad featured a montage of junk food, abdominal fat, as well as statistics about the health risks of obesity and big pharmaceutical firms’ hefty prices. HIMS’ ad then promoted its weight ...

Hims & Hers Health has undeniably captured market attention and investor enthusiasm, fueled by a successful Super Bowl ad campaign and its strategic entry into the high-demand GLP-1 weight loss ...